ALXN2350 gene therapy for dilated cardiomyopathy linked to BAG3 gene changes
Tests ALXN2350 gene therapy in adults with BAG3-related dilated cardiomyopathy.
Key facts
- Who runs it
- Alexion Pharmaceuticals, Inc.
- Where
- London, United KingdomSee the siteAlso in 4 other countries, 11 sites
- Trial code
- Registry title
- ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 6 people, planned
- Started
- 24 Oct 2025
- Expected to end
- 27 Jan 2032
- Type of study
- Interventional
- Treatments tested
- ALXN2350
- Record updated
- 28 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with dilated cardiomyopathy (an enlarged, weakened heart muscle) linked to a change in the BAG3 gene. They get one IV infusion of the gene therapy ALXN2350.
- Age
- 18 Years to 70 Years
- Sex
- All sexes can join.
- Disease stage
- Diagnosed dilated cardiomyopathy (DCM) and chronic heart failure for at least 3 months. NYHA Class I, II or III. LVEF (how well the heart pumps) > 15% and ≤ 45% on echocardiography at Screening. The heart must be clearly visible on an ultrasound (echocardiography).
- Earlier treatment
- People must be on a stable mix of standard heart failure medicines.
- Biomarker or test result
- A pathogenic or likely pathogenic mutation in BAG3 (a disease-causing gene change).
Main reasons for not taking part
- Antibodies to AAV9 in the blood
- A disease-causing gene change in another gene known to cause DCM
- Worsening heart failure that is not under control (decompensated), or NYHA Class IV
- Heart rhythm problems in the lower heart chambers that need treatment
- Serious heart valve disease, or substance abuse that could harm the heart
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Pathogenic or likely pathogenic mutation in BAG3
- Medical history of diagnosis of DCM
- Stable combination of HF SoC medications
- Adequate acoustic windows for echocardiography
- LVEF > 15% and ≤ 45% at Screening by echocardiography
- Diagnosis of chronic HF for at least 3 months
- NYHA Class I/II/III at Screening
Who cannot take part
- Presence of antibodies to AAV9
- Cardiac ventricular arrhythmia that requires treatment
- History of untreated clinically significant valve disease or a Screening confirmation of severe aortic stenosis, severe mitral stenosis, moderate or severe aortic insufficiency or severe mitral insufficiency
- History of substance abuse that could contribute to cardiac dysfunction; Note: Other inclusion and exclusion criteria may apply
- Presence of a pathogenic or likely pathogenic variant in another gene where that other gene is authoritatively recognized as causal for DCM
- Decompensated HF
- NYHA Class IV
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United Kingdom
Also in 4 other countries, 11 sites
- LondonHospital not named in the registryContact: Nikula VicarioTaking people
About the trial
What the trial wants to find out
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
The group in the trial
- ALXN2350Treatment being tested
Participants will receive one of three dose levels of ALXN2350 depending on the cohort.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy
- Plain-language title
- ALXN2350 gene therapy for dilated cardiomyopathy linked to BAG3 gene changesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07218887, who can take part
- Record updated
- 28 August 2026